Nirvana Sciences
Research Triangle Park, US · Delaware corporation · 1 known investors
Nirvana Sciences develops dyes, probes, and contrast agents for life science applications, including organic dyes with narrow emission profiles and a library of over 700 chlorin and bacteriochlorin designs. Its products target life science research and imaging uses.
Founders & leadership
RT
Russell ThomasNamed on SEC filing
Board
RW
Richard WestBoard director
LC
Lisa CooperBoard director
WB
Wayne BrinsterBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$1.7M disclosed across 2 rounds · 2018–2021
▶$867KraisedMay 2021 · 8 investors · Other Health CareRule 506(b)
▶$867KraisedMay 2021 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Richard WestDirector
- Lisa CooperDirector
- Russell ThomasExecutive Officer, Director, Promoter
- Wayne BrinsterDirector
- Offering amount
- $1M
- Amount sold
- $867K
- First sale
- May 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$785.9KraisedJul 2018 · 10 investors · Other Health CareRule 506(b)
▶$785.9KraisedJul 2018 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Richard WestDirector
- Wayne BrinsterDirector
- Russell ThomasExecutive Officer, Director, Promoter
- Lisa CooperDirector
- Offering amount
- $1.5M
- Amount sold
- $785.9K
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 7 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $400K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2014 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Nirvana Sciences do?
- Nirvana Sciences develops dyes, probes, and contrast agents for life science applications, including organic dyes with narrow emission profiles and a library of over 700 chlorin and bacteriochlorin designs. Its products target life science research and imaging uses.
- Who are Nirvana Sciences's investors?
- Nirvana Sciences's investors include IDEA NC.
- How much funding has Nirvana Sciences raised?
- Nirvana Sciences has disclosed $1.7M raised across 2 rounds.
- Where is Nirvana Sciences headquartered?
- Nirvana Sciences is headquartered in Research Triangle Park, US.